Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$136.97 USD

136.97
2,111,504

+0.09 (0.07%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y

Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.

    Arpita Dutt headshot

    6 FDA Events to Watch Out for in May 2017

    Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.

      Merck's Bid to Add Cardiovascular Data on Januvia Label Fails

      Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.

        Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion

        Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.

          Orexigen Inks Commercialization Deal for Contrave, Stock Up

          Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.

            Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays

            We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.

              Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA

              Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.

                Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                  Sheraz Mian headshot

                  Top Analyst Reports for Priceline, Schwab & NextEera Energy

                  Today's Research Daily features new research reports on 16 major stocks, including Priceline (PCLN), NextEra Energy (NEE) and Schwab (SCHW).

                    Novo Nordisk Inks Diabetes Deal with University of Oxford

                    Novo Nordisk A/S (NVO) and University of Oxford announced a landmark research collaboration for the treatment of type II diabetes.

                      Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults

                      Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.

                        Lilly Jardiance Family Diabetes Drugs' Label to be Updated

                        Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.

                          Indradip Ghosh headshot

                          New Strong Sell Stocks for December 27th

                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                            Lilly Stock Surges on Robust 2017 View; Launches Basaglar

                            Eli Lilly and Company (LLY) issued a better-than-expected financial guidance for 2017, alleviating investor concern to a large extent.

                              Eli Lilly (LLY) to Offer Discount on Insulin from January

                              Eli Lilly (LLY) announced that the company will offer access to its insulin products at discounted prices, starting Jan 2017.

                                Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy

                                Eli Lilly and Company (LLY) announced the FDA approval of an extended-release formulation of its type II diabetes prescription drug Synjardy.

                                  Arpita Dutt headshot

                                  Should Biotech Investors Worry About Donald Trump?

                                  It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.

                                    Lilly: Jardiance Label to Add Cardiovascular Indication

                                    Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.

                                      Novo Nordisk Files Regulatory Application for Semaglutide

                                      Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

                                        Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile

                                        Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.

                                          Arpita Dutt headshot

                                          Pharma Industry Stock Outlook - March 2016

                                          Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.

                                            Arpita Dutt headshot

                                            Pharma Industry Stock Outlook - March 2016

                                            Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.